Tiziana Life Sciences Receives FDA Acceptance For Fast Track Designation Submission Of Intranasal Foralumab For Treating Non-Active Secondary-Progressive Multiple Sclerosis (Na-SPMS)
Tiziana Life Sciences Receives FDA Acceptance For Fast Track Designation Submission Of Intranasal Foralumab For Treating Non-Active Secondary-Progressive Multiple Sclerosis (Na-SPMS)
tiziana life sciences獲得FDA接受快速通道指定提交遞交鼻腔foralumab以治療非活動性次進展性多發性硬化症(Na-SPMS)
Tiziana Life Sciences Receives FDA Acceptance For Fast Track Designation Submission Of Intranasal Foralumab For Treating Non-Active Secondary-Progressive Multiple Sclerosis (Na-SPMS)
tiziana life sciences獲得FDA接受快速通道指定提交遞交鼻腔foralumab以治療非活動性次進展性多發性硬化症(Na-SPMS)
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。